The plan revived investors’ appetite for riskier assets and took the wind out of elevated oil prices.
Electricity generator and retailer reports record half-year result.
F&P Healthcare tumbles as softer Cochlear sales add to healthcare chill.
Skellerup set a high benchmark for NZ’s earnings season.
Dual-listed company’s shares fell more than 20% a day before the draft decision was announced to ASX.
After initially forecasting a $5m tariff hit for FY26, the company now expects it will be closer to $2.5m.
Helen Lofthouse is stepping down as chief executive, with no replacement announced as the ASX goes on a global search.
Heine has sailed the company through choppy waters after Steven Newman’s 2022 resignation.
CBA surge buoys Australia’s market.
Regulatory and policy issues in China and the US, which delivers 50% of revenues, have hit Australia’s largest listed biotech company's sales of vaccine and blood plasma products.